Orasis is reshaping vision possibilities. As agile partners to the eye care community, we see every day as an opportunity to disrupt conventional thinking in pursuit of vision without limitations. That is why we reimagined existing and well-studied molecules to create a unique prescription eye drop for presbyopia.
Total raised: $121M
Founded date: 2015
Investors 4
| Date | Name | Website |
| - | Visionary ... | visionaryv... |
| 10.10.2024 | Catalio Ca... | cataliocap... |
| - | LifeSci Ve... | lifesciven... |
| 13.05.2024 | Bluestem C... | bluestemca... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 10.10.2024 | Series D | $78M | - |
| 10.09.2020 | Series C | $30M | - |
| 05.06.2018 | Series B | $13M | - |
Mentions in press and media 6
| Date | Title | Description |
| 10.10.2024 | Orasis Pharmaceuticals: $78 Million (Series D) Raised To Support Launch Of Qlosi | Orasis Pharmaceuticals, a ophthalmic pharmaceutical company focused on reshaping vision possibilities, announced a $78 million Series D round to support the commercial launch of Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, a ... |
| 11.09.2020 | Eye disease biotech Orasis Pharmaceuticals nabs $30M for phase 3, sales activities | A year after a positive readout and two years since its series B round, Orasis Pharmaceuticals has raised a further $30 million. Sponsored by Agilent Technologies How would you like to win free bench space at Lab Central for one scientist f... |
| 11.09.2020 | Eye disease biotech Orasis Pharmaceuticals nabs $30M for phase 3, sales activities | A year after a positive readout and two years since its series B round, Orasis Pharmaceuticals has raised a further $30 million. The Israeli biotech will put the cash to use for late-stage tests of its eye drop candidate for the treatment o... |
| 10.09.2020 | Orasis Raises $30M in Series C Funding | Orasis Pharmaceuticals, a Herzliya, Israel-based ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the treatment of presbyopia symptoms, closed a $30m Series C financing. The round was co-led ... |
| 05.06.2018 | Orasis Pharmaceuticals Closes $13M Series B Financing | Orasis Pharmaceuticals LTD, a Herzliya, Israel-based pharmaceutical company, closed a $13m Series B financing. The round was led by Visionary Ventures, with participation from Sequoia Capital, SBI (Japan) Innovation Ventures, LifeSci Ventur... |
| - | Orasis Pharmaceuticals | “Orasis” |